Clinical Trial Update: ADX10059 Migraine Prevention Study [Phase 2]

View source ↗

Summary

The Phase 2 migraine prevention study of ADX10059 has been terminated. The update does not report final efficacy outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Migraine

Drugs mentioned

• ADX10059

Snippet

Sponsor: Addex Pharma S.A. | Conditions: Migraine | Phase 2 | Status: TERMINATED